[1] Apoorva Gopalakrishna, Sheila A Alexander. Understanding Parkinson Disease: A Complex and Multifaceted Illness[J]. J NeurosciNurs, 2015, 47(6): 320-326.[2] 龙海丽. 帕金森病的诊断治疗和研究进展[J]. 数理医药学杂志, 2017, 30(01): 40-41.[3] 贾振纲, 党丽丽, 李建军, 等. 依达拉奉联合多巴丝肼片治疗血管性帕金森综合征疗效研究[J]. 药物评价研究, 2016, 39(6): 1050-1053.[4] 杨秀峰. 普拉克索联合左旋多巴治疗帕金森病的疗效观察. 中国医药指南[J], 2012, 10(13): 99-100.[5] 王丽云, 刘丽星, 吕海军, 等. 抗帕金森病药物的研究进展[J]. 中国药房, 2017, 28(08): 1143-1149.[6] 秦成玉. 盐酸苯海索治疗帕金森病及帕金森综合征效果观察[J]. 临床合理用药, 2017, 04(10): 75-76.[7] 李彪, 汪瀚, 杨文明. 中医药治疗帕金森病临床研究进展[J/OL]. 辽宁中医药大学学报, 2017, 19(07): 130-133.[8] 罗丕舵, 贾刘云, 王倩, 等. 中医药治疗帕金森病的研究进展[J]. 中医临床研究, 2017, 9(01): 138-140.[9] Jang Y P, Kim S R, Kim Y C. Neuroprotective dibenzylbutyrolactone lignans of Torreya nucifera[J]. Planta Med, 2001, 67(5): 470-472.[10] Rituraj Niranjan. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes[J]. Mol Neurobiol, 2014, 49(1): 28-38.[11] Michelle Smeyne, Richard J Smeyne. Glutathione metabolism and Parkinson's disease[J]. Free Radical Biology and Medicine, 2013, 62: 13-25.[12] Juliet M Taylor, Bevan S Main, Peter J Crack. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease[J]. Neurochem Int, 2013, 62(5): 803-819.[13] Ronald B Postuma, Daniela Berg, Matthew Stern, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. J Movement Disorders Official Movement Disorder Society, 2015, 30(12):1591-1599.[14] 李东薇, 窦德强. 牛蒡苷和牛蒡苷元抗帕金森活性的初步研究[J]. 中国现代医药杂志, 2015, 4(17): 20-22.[15] Chou TC .The median-effect principle and the combination indexfor quant it at ion of synergism and ant agonism[M].In:Chou T C, Rideout D C, ed. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991: 61-102. |